BRPI0912159B8 - copolímero compreendendo um primeiro bloco que compreende uma unidade hidrofílica em ph fisiológico e um segundo bloco que compreende grupos hidrofóbicos, e uso do dito copolímero para liberação intracelular de um polinucleotídeo - Google Patents

copolímero compreendendo um primeiro bloco que compreende uma unidade hidrofílica em ph fisiológico e um segundo bloco que compreende grupos hidrofóbicos, e uso do dito copolímero para liberação intracelular de um polinucleotídeo

Info

Publication number
BRPI0912159B8
BRPI0912159B8 BRPI0912159A BRPI0912159A BRPI0912159B8 BR PI0912159 B8 BRPI0912159 B8 BR PI0912159B8 BR PI0912159 A BRPI0912159 A BR PI0912159A BR PI0912159 A BRPI0912159 A BR PI0912159A BR PI0912159 B8 BRPI0912159 B8 BR PI0912159B8
Authority
BR
Brazil
Prior art keywords
block
copolymer
physiological
copolymers
hydrophobic groups
Prior art date
Application number
BRPI0912159A
Other languages
English (en)
Inventor
S Hoffman Allan
Gall Anna
J Convertine Anthony
L Duvall Craig
Benoit Danielle
S Stayton Patrick
Johnson Paul
Original Assignee
Phaserx Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phaserx Inc, Univ Washington filed Critical Phaserx Inc
Publication of BRPI0912159A2 publication Critical patent/BRPI0912159A2/pt
Publication of BRPI0912159B1 publication Critical patent/BRPI0912159B1/pt
Publication of BRPI0912159B8 publication Critical patent/BRPI0912159B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

copolímero de dibloco e usos dos mesmos descritos aqui são copolímeros, e métodos de preparar e utilizar tais copolímeros. tais copolímero têm pelo menos dois blocos: um primeiro bloco que tem pelo menos uma unidade que é hidrofílica em ph fisiológico, e um segundo bloco que tem grupos hidrofóbicos. este segundo bloco também tem pelo menos uma unidade com um grupo que é aniônico em cerca de ph fisiológico. os copolímeros descritos são disruptivos de uma membrana celular, incluindo uma membrana extracelular, uma membrana intracelular, uma vesícula, uma organela, um endossoma, um lipossoma, ou uma célula de eritrócito. preferivelmente, em certos exemplos, o copolímero rompe a membrana e entra no ambiente intracelular. em exemplos específicos, o copolímero é endossomolítico.
BRPI0912159A 2008-05-13 2009-05-13 copolímero compreendendo um primeiro bloco que compreende uma unidade hidrofílica em ph fisiológico e um segundo bloco que compreende grupos hidrofóbicos, e uso do dito copolímero para liberação intracelular de um polinucleotídeo BRPI0912159B8 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US5290808P 2008-05-13 2008-05-13
US5291408P 2008-05-13 2008-05-13
US9129408P 2008-08-22 2008-08-22
US11204808P 2008-11-06 2008-11-06
US11205408P 2008-11-06 2008-11-06
US12076908P 2008-12-08 2008-12-08
US14077408P 2008-12-24 2008-12-24
US14077908P 2008-12-24 2008-12-24
US17137709P 2009-04-21 2009-04-21
PCT/US2009/043847 WO2009140427A2 (en) 2008-05-13 2009-05-13 Diblock copolymers and polynucleotide complexes thereof for delivery into cells

Publications (3)

Publication Number Publication Date
BRPI0912159A2 BRPI0912159A2 (pt) 2015-10-13
BRPI0912159B1 BRPI0912159B1 (pt) 2019-11-05
BRPI0912159B8 true BRPI0912159B8 (pt) 2021-05-25

Family

ID=41319323

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912159A BRPI0912159B8 (pt) 2008-05-13 2009-05-13 copolímero compreendendo um primeiro bloco que compreende uma unidade hidrofílica em ph fisiológico e um segundo bloco que compreende grupos hidrofóbicos, e uso do dito copolímero para liberação intracelular de um polinucleotídeo

Country Status (13)

Country Link
US (3) US9476063B2 (pt)
EP (2) EP2620161A1 (pt)
JP (2) JP5911723B2 (pt)
KR (1) KR101661636B1 (pt)
CN (2) CN103342789B (pt)
AU (1) AU2009246327B8 (pt)
BR (1) BRPI0912159B8 (pt)
CA (3) CA3065577C (pt)
ES (1) ES2404131T3 (pt)
IL (1) IL209238A (pt)
MX (1) MX2010012238A (pt)
WO (1) WO2009140427A2 (pt)
ZA (1) ZA201008729B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523641A (ja) * 2008-05-13 2011-08-18 ユニヴァーシティ オブ ワシントン 高分子キャリア
EP2285853B1 (en) 2008-05-13 2013-02-27 University of Washington Micellic assemblies
KR101661636B1 (ko) 2008-05-13 2016-09-30 유니버시티 오브 워싱톤 세포로의 전달을 위한 이블록 공중합체 및 그의 폴리뉴클레오티드 복합체
CA2734917A1 (en) 2008-08-22 2010-02-25 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
MX2011004242A (es) 2008-11-06 2011-07-20 Univ Washington Copolimeros multibloque.
WO2010077678A2 (en) 2008-12-08 2010-07-08 University Of Washington Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization
WO2011060281A1 (en) * 2009-11-13 2011-05-19 University Of Washington Through Its Center For Commercialization Hydrophobic block conjugated therapeutic agents
US9415113B2 (en) 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140051357A (ko) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012308686B2 (en) * 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2012377385A1 (en) * 2012-04-18 2014-01-23 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
US9808480B2 (en) 2012-04-27 2017-11-07 Nanocarrier Co., Ltd. Unit structure-type pharmaceutical composition for nucleic acid delivery
AR091143A1 (es) 2012-05-24 2015-01-14 Seeds Ltd Ab Composiciones y metodos para silenciar la expresion genetica
WO2014047524A1 (en) 2012-09-21 2014-03-27 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
US10046086B2 (en) 2012-09-21 2018-08-14 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2919828C (en) 2013-07-30 2022-07-19 Phaserx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
KR102390075B1 (ko) 2014-03-09 2022-04-26 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 오르니틴 트랜스카르바밀라아제（ｏｔｃ） 결핍증의 치료에 유용한 조성물
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) * 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
EP3125946B1 (en) * 2014-03-28 2022-12-07 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US10695288B2 (en) 2014-11-19 2020-06-30 Vanderbilt University Reactive oxygen species (ROS)-responsive compositions and methods thereof
CN114642735A (zh) * 2015-01-21 2022-06-21 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
WO2016176191A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
EP3325018A4 (en) 2015-07-22 2019-04-24 Duke University HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES
CA2996001A1 (en) 2015-08-25 2017-03-02 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EP3421517B1 (en) * 2016-03-29 2019-09-11 LG Chem, Ltd. Block polymer and polymer electrolyte membrane comprising same
EP4101859A1 (en) 2016-09-02 2022-12-14 Dicerna Pharmaceuticals, Inc. 4'-oxymethylphosphonate nucleotide analogs and oligonucleotides comprising the same
EP3562510A4 (en) 2016-12-30 2021-01-06 Genevant Sciences GmbH BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES
CN110402152B (zh) 2017-01-09 2024-03-19 艾博森斯有限公司 用于分子的跨膜递送的化合物和方法
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
US11324835B2 (en) 2017-08-31 2022-05-10 Kawasaki Institute Of Industrial Promotion Nucleic acid-loaded unit polyion complex
US20220008346A1 (en) * 2018-10-30 2022-01-13 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
WO2020145206A1 (ja) * 2019-01-09 2020-07-16 デンカ株式会社 トリブロック共重合体及びトリブロック共重合体の製造方法
MX2021011928A (es) 2019-03-29 2022-01-04 Dicerna Pharmaceuticals Inc Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras.
US20220177880A1 (en) 2019-05-03 2022-06-09 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
MX2022008738A (es) 2020-01-15 2022-09-23 Dicerna Pharmaceuticals Inc Acidos nucleicos de fosfonato de 4'-o-metileno y analogos de estos.
EP4143248A1 (en) * 2020-04-30 2023-03-08 Dow Global Technologies LLC Process for preparing olefin-acrylate block copolymers by raft polyerization
EP4192505A1 (en) 2020-08-04 2023-06-14 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
CN113087017A (zh) * 2021-04-06 2021-07-09 中国科学院理化技术研究所 一种偏钒酸钠纳米球及其制备方法和应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877603A (en) 1987-12-18 1989-10-31 The Procter & Gamble Company Oral compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
FR2767829B1 (fr) 1997-09-01 1999-12-03 Georges Sturtz Composes phosphonates ou gem-bisphosphonates acryliques ou methacryliques
EP1037611B1 (en) 1997-12-12 2008-10-29 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
US6410057B1 (en) * 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
US6383811B2 (en) * 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
EP2138191A1 (en) * 1998-01-05 2009-12-30 University Of Washington Enhanced transport using membrane disruptive agents
US6306994B1 (en) * 1999-05-14 2001-10-23 E. I. Du Pont De Nemours And Company Inks with enhanced substrate binding characteristics
US7098032B2 (en) * 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US7033607B2 (en) * 1999-12-31 2006-04-25 Mirus Bio Corporation pH-titratable polyampholytes for delivering polyions to a cell
US7737108B1 (en) * 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents
US20030134420A1 (en) * 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
AU2001276627A1 (en) 2000-05-17 2001-11-26 Labopharm Inc. Drug containing polymeric micelles
EP1325046B1 (en) 2000-10-06 2007-06-27 Biocompatibles UK Limited Zwitterionic polymers
SE517421C2 (sv) * 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
AU2002367709A1 (en) 2001-04-26 2003-10-27 Nanosphere, Inc. Oligonucleotide-modified romp polymers and co-polymers
US7094810B2 (en) * 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6780428B2 (en) * 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US20030191081A1 (en) * 2001-12-28 2003-10-09 Pierre Lemieux Pharmaceutical compositions and methods of use thereof comprising polyanionic polymers and amphiphilic block copolymers to improve gene expression
EP1480619B1 (en) * 2002-03-07 2013-08-07 Biocompatibles UK Limited Drug carriers comprising amphiphilic block copolymers
US7229973B2 (en) 2002-05-19 2007-06-12 You Han Bae pH-sensitive polymeric micelles for drug delivery
EP1400555A1 (en) 2002-09-17 2004-03-24 Kawamura Institute Of Chemical Research Water-soluble block copolymer and production method therefor
JP2006505686A (ja) 2002-11-07 2006-02-16 ロディア・シミ 両性又は双極性イオン性部分を含む制御された構造のコポリマー
US20070010632A1 (en) * 2002-11-27 2007-01-11 Kaplan David L Antioxidant-functionalized polymers
CA2508015C (en) * 2002-12-30 2012-04-03 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
US7871818B2 (en) * 2003-01-31 2011-01-18 Roche Madison Inc. Membrane active polymers
US7217776B1 (en) * 2003-02-14 2007-05-15 Iowa State University Research Foundation pH-sensitive methacrylic copolymer gels and the production thereof
US20040162235A1 (en) * 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
JP4535229B2 (ja) * 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
FR2868784B1 (fr) * 2004-04-09 2006-05-26 Oreal Copolymere sequence, composition le comprenant et procede de traitement cosmetique
US7632905B2 (en) 2004-04-09 2009-12-15 L'oreal S.A. Block copolymer, composition comprising it and cosmetic treatment process
US20080274454A1 (en) 2004-04-07 2008-11-06 Mirkin Chad A Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles
US8821859B2 (en) * 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
GB0418123D0 (en) * 2004-08-13 2004-09-15 Asahi Chemical Ind Polymers useful as medical materials
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
WO2006071769A1 (en) * 2004-12-28 2006-07-06 The Trustees Of The University Of Pennsylvania Controlled release from block co-polymer worm micelles
US20060171980A1 (en) * 2005-02-01 2006-08-03 Helmus Michael N Implantable or insertable medical devices having optimal surface energy
KR20070122521A (ko) * 2005-03-31 2007-12-31 에이피 파마, 인코포레이티드 Ｐｅｇ-폴리아세탈 및 ｐｅｇ-폴리아세탈-ｐｏｅ 그래프트공중합체 및 약학 조성물
EP1868664A2 (en) * 2005-04-15 2007-12-26 Interface Biologics Inc. Methods and compositions for the delivery of biologically active agents
US9139850B2 (en) * 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
US9505867B2 (en) 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
FR2890859B1 (fr) * 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
US7718193B2 (en) * 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
WO2007133807A2 (en) * 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
CN101501108A (zh) 2006-07-05 2009-08-05 新加坡科技研究局 用于药物递送的胶束
CN102614528B (zh) 2006-08-18 2014-02-26 箭头研究公司 用于体内递送多核苷酸的多缀合物
WO2008085556A2 (en) 2006-09-12 2008-07-17 University Of South Florida Surfactant-free nanoparticles for drug delivery
US20080081075A1 (en) * 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
WO2008071009A1 (en) 2006-12-15 2008-06-19 The Governors Of The University Of Alberta Novel ligand guided block copolymers for targeted drug delivery
CA2916671C (en) * 2007-01-17 2018-01-09 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US20080312581A1 (en) * 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Peptosomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
WO2008148174A1 (en) 2007-06-08 2008-12-11 Queensland University Of Technology Wound repair composition and method
EP2173168A1 (en) 2007-06-11 2010-04-14 BioCure, Inc. Vesicles for active macromolecule delivery
CA2692748A1 (en) 2007-07-06 2009-01-15 Northeastern University Mixed micelles including amphipathic conjugates of rna agents, and uses thereof
US20090036625A1 (en) * 2007-08-01 2009-02-05 Chung Yuan Christian University Amphiphilic Polymer, Method for Forming the Same and Application thereof
EP2025348A1 (en) 2007-08-13 2009-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Targeted block copolymer micelles
JP2011523641A (ja) 2008-05-13 2011-08-18 ユニヴァーシティ オブ ワシントン 高分子キャリア
WO2009140423A2 (en) 2008-05-13 2009-11-19 University Of Washington Targeted polymer bioconjugates
US20110142951A1 (en) 2008-05-13 2011-06-16 University Of Washington Micelles for intracellular delivery of therapeutic agents
EP2285853B1 (en) 2008-05-13 2013-02-27 University of Washington Micellic assemblies
KR101661636B1 (ko) 2008-05-13 2016-09-30 유니버시티 오브 워싱톤 세포로의 전달을 위한 이블록 공중합체 및 그의 폴리뉴클레오티드 복합체
CA2734917A1 (en) 2008-08-22 2010-02-25 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
DK2180004T3 (da) 2008-10-22 2011-09-05 Clariant Finance Bvi Ltd Olefinisk umættede phosphonatforbindelser, polymere fremstillet ud fra disse og deres anvendelse
EP2352522A4 (en) * 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US20110281934A1 (en) * 2008-11-06 2011-11-17 Phaserx, Inc. Micelles of hydrophilically shielded membrane-destabilizing copolymers
MX2011004242A (es) * 2008-11-06 2011-07-20 Univ Washington Copolimeros multibloque.
US20100150952A1 (en) * 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
WO2010077678A2 (en) 2008-12-08 2010-07-08 University Of Washington Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization

Also Published As

Publication number Publication date
CA2724105C (en) 2017-09-05
US20170096517A1 (en) 2017-04-06
EP2281011A2 (en) 2011-02-09
US20110143434A1 (en) 2011-06-16
ZA201008729B (en) 2014-05-28
JP6239565B2 (ja) 2017-11-29
CA2724105A1 (en) 2009-11-19
AU2009246327A8 (en) 2011-01-13
CA2972694C (en) 2020-02-11
JP2016053169A (ja) 2016-04-14
IL209238A0 (en) 2011-01-31
CN102083878B (zh) 2013-07-10
BRPI0912159B1 (pt) 2019-11-05
KR20110033124A (ko) 2011-03-30
WO2009140427A3 (en) 2010-03-04
CN103342789A (zh) 2013-10-09
US9862792B2 (en) 2018-01-09
CN103342789B (zh) 2016-11-23
BRPI0912159A2 (pt) 2015-10-13
US20180171056A1 (en) 2018-06-21
ES2404131T3 (es) 2013-05-24
IL209238A (en) 2014-03-31
EP2620161A1 (en) 2013-07-31
AU2009246327B2 (en) 2013-09-12
JP2011521054A (ja) 2011-07-21
AU2009246327A1 (en) 2009-11-19
CA3065577C (en) 2022-05-31
JP5911723B2 (ja) 2016-04-27
CA3065577A1 (en) 2009-11-19
WO2009140427A2 (en) 2009-11-19
EP2281011A4 (en) 2011-10-26
EP2281011B1 (en) 2013-02-27
CA2972694A1 (en) 2009-11-19
KR101661636B1 (ko) 2016-09-30
MX2010012238A (es) 2011-04-11
AU2009246327B8 (en) 2013-10-03
US9476063B2 (en) 2016-10-25
CN102083878A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
BRPI0912159B8 (pt) copolímero compreendendo um primeiro bloco que compreende uma unidade hidrofílica em ph fisiológico e um segundo bloco que compreende grupos hidrofóbicos, e uso do dito copolímero para liberação intracelular de um polinucleotídeo
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BRPI1015994A2 (pt) copolímero em bloco de poliéter sulfona aromática, processo para preparar copolímetros em bloco de poliéter sulfona aromática, uso dos copolímeros em bloco de poliéter sulfona aromática, célula de combustível, e, membrana para o tratamento de água.
BRPI0514294A (pt) material compósito, processo para preparar o mesmo, método para remover um material de uma solução aquosa, aparelho de filtração, e, membrana de ultrafiltração
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
BR112014031220A2 (pt) estrutura de eletrodo com capacidade de respiração e método e sistema para uso em separação da água
BR112015001620A2 (pt) composição de meio de cultura, e método para cultivo de célula ou tecido usando-se dita composição
DE602006016941D1 (de) Verfahren und system zur absoluten bestimmung einer prozentualen plättchenhäufung
WO2011106456A3 (en) Artificial mycolic acid membranes
BRPI1011760A2 (pt) método para prevenir ou reduzir coagulação no trato gastrointestinal superior de um indivíduo, e, uso de proteína anticoagulante.
BRPI0922570B8 (pt) uso de uma preparação à base de água, biocompatível, de um kit, e, preparação à base de água, biocompatível
BR112012007174A8 (pt) Método para filtrar líquido, e, dispositivo de filtração de líquido
AR063795A1 (es) Microorganismos como vehiculos de secuencias de nucleotidos codificantes de antigenos y toxinas proteicas, proceso de elaboracion y usos de los mismos
BRPI0516161A (pt) material compósito, e, aparelho de filtração
ATE474005T1 (de) Sulfoniertes copolymer
BRPI0511802A (pt) processo para criação de meios para uso em separadores de ar/óleo
BR112012029516B1 (pt) dispositivo de retenção de tecido
ATE482981T1 (de) Wässrige monomeremulsionen enthaltend hydrophobin
DE602006009915D1 (de) Verfahren zur herstellung gepfropfter polylysin-dendrimere
BR112013007705A2 (pt) solução tendo uma composição de copolímero em bloco sulfonado, película ou membrana, dispersão aquosa, compósito, composição de copolímeto em bloco sulfonado, processo, método para formar uma composição de copolímero em bloco sulfonado, e, célula eletrodialítica
WO2014100481A8 (en) Modified alpha hemolysin polypeptides and methods of use
EP3495398A4 (en) COPOLYMER AS WELL AS SEPARATION MEMBRANE, MEDICAL DEVICE AND BLOOD PURIFIER IN WHICH THIS COPOLYMER IS USED
ATE519772T1 (de) Vorrichtung und system mit trockener kontrollgen- verstummungszusammensetzung
BR112017018345A2 (pt) copolímeros como excipientes para a solubilização eficaz de substâncias fracamente solúveis em água a partir de misturas sólidas
WO2016081810A8 (en) System for the concomitant assessment of drug dissolution, absorption and permeation and methods of using the same

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF